Evaluation of genotypic resistance of HIV-1 in patients with virologic failure Guatemala
DOI:
https://doi.org/10.36829/63CTS.v1i1.11Abstract
ARV drug resistance is one of the leading causes of virologic failure among HIV patients on HAART. The objective of this study was to determine genotypic resistance profiles among HIV patients on virologic failure. Patients from one HIV clinic in Guatemala on whom ARV drug resistance was suspected and needed a change in their ARV regimen due to virologic failure were included. In order to perform the genotype, the patient had to demonstrate good adherence to therapy and a confirmed viral load ≥1,000 copies/ml. Demographics and clinical data were collected through the resistance-testing questionnaire. The TRUGENE® HIV-1 methodology was used for resistance analysis. The patient sample was restricted to 25 patients due to accessibility, 68% presented resistance to at least one ARV drug. By ARV class, 88.2% presented resistance to NNRTIs, 70.5% to NRTIs and 17.6% to IPs. We found 79 mutations among the samples analyzed. Of the mutations found, 46.8% were associated with NNRTI resistance, 76.6% to NRTI resistance and the remainder 26.6% to PI resistance. The most frequent NRTI associated mutations were M184V 43%, M184I 14% and K219E 10%; 23.8% were TAM. The NNRTI associated mutations were V179D 16%, K103N 14%, G190A 14% and Y181C 14%. For the PI the most frequent mutation was M36I with 29%. The resistance found in this study was lower to that reported in other Latin American studies, however, it is similar to what is reported by WHO in low and middle income countries.
Downloads
References
Alave, J., Paz, J., González, E., Campos, M., Rodríguez, M., Willing, J. y Echeverría, J. (2013). Factores asociados a falla virológica en pacientes infecta- dos con VIH que reciben terapia anti-retroviral en un hospital público del Perú. Revista Chilena de Infectología, 30, 42-48. https://doi.org/10.4067/S0716-10182013000100006
Bennet, D., Bertagnolio, S., Sutherland, D., & Gilks, C. (2008). The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antiviral Therpy, 13, Supplement 2: 1-13.
Biosciences. (2008). BD FACSCOunt CD4 reagentes. Diallo, K., Goette, M., & Wainberg, M. (2003). Molecu- lar Impact of the M184V Mutation in Human Im- munodeficiency Virus Type 1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy, 47, 3377-3383. https://doi.org/10.1128/AAC.47.11.3377-3383.2003
Diazgranados, C., Silva, A., Bermudez, A., Rooncacio, D., Diruggiero, P., & Mantilla, M. (2007). Rate and Predictors of optimal virologic response to antiretroviral therapy. International Journal of Infectious Diseases, 11, 531-535. https://doi.org/10.1016/j.ijid.2007.03.002
Gale, H., Kan, V., & Shinol, R. (2006). Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter. Clinical Vaccine Immunology, 13, 235-238. https://doi.org/10.1128/CVI.13.2.235-238.2006
Grant, R., Kuritzkes, D., Johnson, V., Mellors, J., Sullivan, J., Swanstrom, R., ... Winslow, D. (2003). Accuracy of the TRUGENE HIV-1 Genotyping Kit. Journal of Clinical Microbiology, 41, 1586- 1593. https://doi.org/10.1128/JCM.41.4.1586-1593.2003
Luber, A. (2005). Genetic barriers to resistance and impact on clinical response. Medscape General Medicine, 7, 69-92. https://doi.org/10.1186/1758-2652-7-3-69
Ministerio de Salud Pública y Asistencia Social. (2010). Guía de tratamiento antirretroviral y de infeccio- nes oportunistas en Guatemala. Autor
Ministerio de Salud Pública y Asistencia Social. (2010). Programa Nacional de Prevención y Control de ITS, VIH, y SIDA. Informe de Progreso UNGASS. Guatemala: Autor
Ministerio de Salud Pública y Asistencia Social. (2012). Programa Nacional de Prevención y Control de ITS, VIH, y SIDA. Informe de Progreso UNGASS. Guatemala. Autor
Nachega, J., Marconi, V., van Zyl, G., Gardener, E., Preiser, W., Hong, S., ... Gross, R. (2011). HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infectious Disorders - Drug Targets, 11, 167-174. https://doi.org/10.2174/187152611795589663
Organización Mundial de la Salud. (2010). Antiretroviral therapy for HIV infection in adults and adolescents. Autor
Organización Mundial de la Salud. (2011). Marco de acción del Tratamiento 2.0: Impulsando la próxi- ma generación del tratamiento, la atención y el apoyo. Autor
Organización Mundial de la Salud. (2012). WHO HIV Drug resistance report 2012. Autor
Organizacion Panamericana de Salud. (2012). Trata- miento antirretroviral bajo la lupa: un análisis de salud pública en Latinoamérica y el Caribe. Autor
Palella, F., Delaney, K., Moorman, A., Loveless, M., Fuhrer, J., Satten, G. …Holmberg, S. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal Medicine, 13, 853-860. https://doi.org/10.1056/NEJM199803263381301
Parienti, J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., Larouzé, B., & Verdon, R. (2004). Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clinical Infectious Diseases, 38, 1311-1316. https://doi.org/10.1086/383572
Ríos, M., Delgado, E., Pérez-Alvarez, L., Fernández, J., Gálvez, P., de Parga, E., ... Nájera, R. (2007). Antiretroviral drug resistance and phylogenetic diversity of HIV-1 in Chile. Journal of Medical Virology, 79, 647-56. https://doi.org/10.1002/jmv.20881
Safer, R. (2010). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clinical Microbiology Reviews 15, 247-277. https://doi.org/10.1128/CMR.15.2.247-277.2002
Sendi, P., Günthard, H., Simcock, M., Ledergerber, B., Schüpbach, J., Battegay, M., & Swiss HIV Cohort Study (2007). Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. Plos ONE, 1-8. https://doi.org/10.1371/journal.pone.0000173
Stanford University. (2012). HIV Drug Resistance Data Base. http://hivdb.stanford.edu/index.html
Strauss, K., Hannet, I., Engels, S., Shiba, A., Ward, D., Ullery, S., ... Kestens, L. (1996). Performance evaluation of the FACSCount System: a dedicated system for clinical cellular analysis. Cytometry, 26, 52-59. https://doi.org/10.1002/(SICI)1097-0320(19960315)26:1<52::AID-CYTO8>3.0.CO;2-I
van de Vijver, D., Wensing, A., Åsjö, B., Bruckova, M., Jorgensen, L., Camacho, R., ... Boucher, C. (2010). HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries. Acta Dermatovenerologica Alpina, Pannoica et Adriatica, 19, 3-9.
van Oosterhout, J., Brown, L., Weigel, R., Kumwenda, J., Mzinganjira, D., Saukila, N., ... Hosseinipour, M. (2009). Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Tropical Medicina & International Health, 14(8), 856-61. https://doi.org/10.1111/j.1365-3156.2009.02309.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2014 Blanca Samayoa, Anneliese Moller, Narda Medina, Eduardo Arathoon, Dalia Lau-Bonilla
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
El autor que publique en esta revista acepta las siguientes condiciones:
- El autor otorga a la Dirección General de Investigación el derecho de editar, reproducir, publicar y difundir el manuscrito en forma impresa o electrónica en la revista Ciencia, Tecnología y Salud.
- La Direción General de Investigación otorgará a la obra una licencia Creative Commons Atribución-NoComercial-CompartirIgual 4.0 Internacional
